Lannett Company Inc.
| Company Name | Lannett Company Inc. |
| Stock Symbol | LCI |
| Class Period | July 15, 2014 to October 31, 2017 |
| Lead Plaintiff Motion Deadline | January 17, 2017 |
The Firm announces an investigation on behalf of Lannett Company Inc. (“Lannett”) or the “Company”) (NYSE: LCI) investors concerning recent reports that the Company has unlawfully colluded with other pharmaceutical companies to fix generic drug prices.
According to news reports United States prosecutors may file criminal charges against Lannett by the end of 2016 for suspected price collusion.
Bloomberg News has reported that the, “antitrust investigation by the Justice Department, begun about two years ago, now spans more than a dozen companies and about two dozen drugs, according to people familiar with the matter. The grand jury probe is examining whether some executives agreed with one another to raise prices, and the first charges could emerge by the end of the year, they said.”
The companies identified as targets or relevant parties in the United States investigation include Mylan NV, Teva Pharmaceutical Industries Ltd, Allergan Plc, Lannett Co., Impax Laboratories Inc., Sun Pharmaceutical Industries Ltd., Mayne Pharma Group Ltd., Endo International Plc and Taro Pharmaceutical Industries Ltd.
On this news, Lannett stock fell $6.25 per share, or nearly 27%, to close at $17.25 per share on November 3, 2016.
If you purchased Lannett securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224 or by email to shareholders@glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
Submit Your Information
If you suffered a loss on your Lannett Company Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.